Concepedia

Perry S. Sawyer

PS

Statistics

Publications

6

Citations

1.4K

H-Index

6

Active since

1986

Affiliations

Pfizer (United States)(Current)

Perry S. Sawyer is an author at Pfizer (United States) specializing in pharmacology, jak-stat signaling pathway, and jak inhibitors.

Publications per year

1986–2010

6

Publications

6

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

, , +17

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

, , +17

The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models

Elizabeth M. Kudlacz, Bret D. Perry, Perry S. Sawyer et al. · American Journal of Transplantation · 2003 · 154 citations

, , +14

Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection

James A. Retsema, A. R. English, Agnès Girard et al. · Clinical Infectious Diseases · 1986 · 106 citations

, , +17

The specificity of JAK3 kinase inhibitors

Paul S. Changelian, Deborah Moshinsky, Cyrille Kuhn et al. · Blood · 2007 · 95 citations · Full text

, , +11

1–5 of 6